Navigation Links
New test promises quicker, more accurate evaluation for cystic fibrosis patients
Date:10/23/2008

Researchers at National Jewish Health have identified a simple gene-based blood test that more accurately and quickly measures cystic fibrosis patients' response to therapy than current tests. The test, a measure of inflammatory gene expression, could improve patient care and help clear a backlog of promising medications now hung up in clinical trials. The researchers recently published the results of a small "proof-of-principal" trial in the online version of American Journal of Respiratory and Critical Care Medicine, and will also publish them in a future print issue.

"The currently accepted test, a measure of a patients' ability to exhale air, has several limitations that make it ineffective for some patients and not sensitive enough for clinical trials of many new medications," said Dr. Milene Saavedra, lead author of the study and Assistant Professor of Medicine at National Jewish Health. "By measuring the activity of genes associated with the immune/inflammatory response, we can get a more accurate picture of the biological processes occurring inside the lungs."

Cystic fibrosis is the most common lethal inherited disease in the western world, with about 30,000 patients in the US. Most patients die of respiratory failure generally in their 30s or 40s. Lung damage is caused primarily by chronic bacterial infections and the resulting severe airway inflammation. There is a critical need for new effective anti-microbial and anti-inflammatory medications to slow and/or prevent lung damage in young patients. Several promising therapies have gone through early stages of clinical testing but their progress is being hampered by the lack of a sensitive measure of therapeutic response to medications.

Currently, response to medication is measured by how much air a person can rapidly exhale: forced expiratory volume in one second or FEV1. FEV1 cannot be performed effectively for all patients, especially young and very sick patients. Generally patient
'/>"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Innovative civil engineering application promises cleaner waters
2. New CPR promises better results by compressing abdomen, not Chest
3. Prototype terahertz imager promises biochem advances
4. Telescope embedded in glasses lens promises to make driving easier for visually impaired
5. Genetic data promises new future for kiwi fruit
6. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
7. Voice Biometrics Gains Traction as Most Accurate and Convenient Technology to Secure Customer Privacy
8. Scripps scientists develop new tests that identify lethal prion strains quickly and accurately
9. Safer, more accurate radiation therapy for expecting mothers
10. Swish-and-spit test accurate for cancer
11. New research suggests biofuel blending is often inaccurate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... spelled doom for the dinosaurs 66 million years ago ... much greater extent than their deciduous peers, according to ... published in the journal PLOS Biology . ... thousands of fossilized leaves of angiosperms flowering ... reconstruct the ecology of a diverse plant community thriving ...
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... has found all forms of tobacco exposure, whether that be ... of heart attack. , The study by professors Salim Yusuf ... Medicine at McMaster University and Hamilton Health Sciences in Hamilton, ... In collaboration with colleagues from 52 countries, they calculated the ...
... Researchers have found that abnormal stimulation of a ... cells in adults causes invasive tumor-like growths in ... to regress--a finding the researchers said suggests a ... called malignant gliomas. , Arturo Alvarez-Buylla and Erica ...
... savannas contain 70% of the world's plants and are critical ... project involving researchers from the Leeds Earth and Biosphere Institute ... sensitive areas. , The researchers think we may be at ... the rainforests to shrink, so increasing the amount of carbon ...
Cached Biology News:Global study shows all tobacco bad for the heart 2Global study shows all tobacco bad for the heart 3Possible birthplace of malignant brain tumors identified 2The vicious cycle of rainforest destruction 2
(Date:9/17/2014)... 2014  MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed ... another peer-reviewed clinical study.    The ... Controlled Clinical Trial Evaluating the Use of ... Multi-layer Compression Therapy vs. Multi-layer Compression Therapy Alone ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of a ... This addition to the company’s industry-leading line of custom ... available in 125 or 250 gallon capacities. It ... or less. , The new pre-engineered TerraPure tank offers ... TerraPure tank line – plus quick turnaround. An ...
(Date:9/17/2014)... , Sept. 17, 2014 Veracyte, Inc. ... company pioneering the field of molecular cytology, today announced ... officer. Mr. Hall joined Veracyte in 2010 ... entry into endocrinology. Since 2012, he has led sales, ... managed care and billing functions. As chief operating officer, ...
(Date:9/17/2014)... , September 17, 2014 ... mode of action from a truly novel ... MGB Biopharma, a biopharmaceutical company ... announces today that it has secured £4.0m ... lead antibacterial, MGB-BP-3, against a range of ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Stock Exchange Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), announced that effective on ... purchase warrants, each of which entitles the holder to ... of $5.00 per share, will be extended from March ...
... B.C. Technology Promises to Revolutionize Food Processing, ... Corporation (TSX-V: ENW) ("EnWave" or "the Company") today ... of its continuous nutraREV(TM) food dehydration equipment to ... of B.C.,s largest blueberry producers. With this sale, ...
... of "In the Zone for UC" Campaign, Centocor Ortho ... Colitis Foundation of America for Each Point Pisani Scores ... Ortho Biotech Inc. announced today a partnership with professional ... colitis (UC) and funding to support continued education and ...
Cached Biology Technology:BioMS Medical warrant extension 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4
... C1 Plus is a modular confocal system ... with an ultra-compact and lightweight design. The ... Plusboost optical performance to 400nm andits bi-directional ... support for X and Y scan axes ...
... integrated digital microscope and camera system that ... optical adjustment or software installation. Built on ... combines simplicity and advanced technology for users ... viewing of a macro image and a ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... The Fujifilm Life Science LAS-3000 ... technology with a simplified user interface, ... a wide range of modularities. The ... applications, and the perfect standard system ...
Biology Products: